Darovasertib Combination Data in HLA*A2:01 Negative Metastatic Uveal Melanoma Reported at ASCO

**FOR IMMEDIATE RELEASE**

**IDEAYA Biosciences and Servier Announce Complete Data from Phase 2/3 OptimUM-02 Trial of Darovasertib Combination in Metastatic Uveal Melanoma**

IDEAYA Biosciences and Servier presented complete data from their Phase 2/3 OptimUM-02 trial, which investigated the efficacy of the darovasertib combination in first-line HLA*A2:01 negative metastatic uveal melanoma. The findings were shared in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting.

The OptimUM-02 trial focused on patients with HLA*A2:01 negative metastatic uveal melanoma who had not previously received treatment. The study evaluated the combination of darovasertib with other therapies. Researchers aimed to assess the safety and effectiveness of this treatment approach in this specific patient population. The complete data set provides a comprehensive analysis of the trial’s outcomes, offering insights into the potential benefits and limitations of the darovasertib combination in treating this challenging form of melanoma.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI